Our Pipeline: First-In-Class
Bicara has more than a platform: We have a deep pipeline of promising bifunctional antibodies and other biologics for treating solid tumors, including a lead program that’s already in the clinic.
- PROGRAMTARGETDISCOVERYIND-ENABLINGPHASE 1PHASE 2PHASE 3Indication
- BCA101EGFR / TGF-βEGFR / TGF-βcSCCHNSCC, SCAC
- BCA356precision immunocytokineprecision immunocytokineSolid Tumors
- BCA600precision immunecell engagerprecision immunecell engagerSolid Tumors
- BCA500UndisclosedUndisclosedSolid Tumors
We have taken a pragmatic approach to building our pipeline. We seek out a powerful biological rationale and strong potential to address significant unmet needs, which include patients who are refractory to immune checkpoint inhibitors and first-line targeted therapies.
Posters and Publications
Poster Presentation: Development of BCA101, a Bifunctional Antibody Capable of Simultaneously Disabling EGFR and TGF-β Signaling, as a Novel Single-agent Immunotherapy
Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting, November 2021
Digital Presentations: First-in-human Phase I Study of the Bifunctional EGFR/TGFβ Fusion Protein BCA101 in Patients with EGFR-driven Advanced Solid Cancers
American Society of Clinical Oncology, June 2021
Our Lead Program: BCA101
First-in-class EGFR / TGFβ-trap bifunctional antibody
Epidermal growth factor receptor (EGFR), a protein expressed on the surface of several tumor types, is one of the most extensively validated tumor-associated antigens.
Monoclonal antibodies directed at EGFR suppress the proliferation of EGFR-driven tumor cells and restrict tumor growth and metastasis. Inhibiting EGFR alone is inadequate to achieve durable therapeutic responses. Our solution: Simultaneous inhibition of EGFR and TGFβ — a signaling molecule that promotes tumor growth in the presence of EGFR and that plays a key role in suppressing the immune response in the tumor microenvironment.
Our lead program is thus a dual-action bifunctional antibody that both inhibits EGFR and disables TGFβ directly at the site of the tumor. With this approach, we hope to achieve superior anti-tumor efficacy with an improved therapeutic window.
Phase 1/2 Clinical Study
We have completed dose escalation studies evaluating BCA101 as a single-agent and in combination with pembrolizumab, and have initiated the dose expansion arm of our clinical study.
BCA101 will be administered in combination with pembrolizumab as first-line therapy in patients with unresectable, recurrent or metastatic HNSCC and as second-line therapy in patients with advanced SCAC who have received prior chemotherapy. A third cohort of patients with advanced or incurable cSCC who have received previous anti-PD-1 therapy will be treated with BCA101 as a single agent.
For more information, please visit clinicaltrials.gov.
Enrolling trial sites
Houston, TX
New York, NY
Boston, MA
Toronto, ON
New York, NY
Pittsburgh, PA
Charleston, SC
Los Angeles, CA
San Diego, CA
Tampa, FL
Cleveland, OH
Providence, RI